Pancreatic Cancer Research

ResearcherUniversidade Federal da BahiaActive in the last 2 years

Andrea Pretta

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0262-9270; OpenAlex author ID A5003848263. Sources: OpenAlex.

Their work

Papers
11
Trials
0
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 3 papers · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 3 papers

Papers 11

  1. Short-term versus long-course neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results f… Co-author DOI 10.1016/j.eclinm.2026.104190↗
  2. Impact of diabetes mellitus on treatment efficacy in patients with advanced pancreatic cancer: the Italian, multicenter, observational PANCAKE study. Co-author DOI 10.1016/j.esmogo.2025.100276↗
  3. Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection. Co-author DOI 10.1093/oncolo/oyag085↗
  4. Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score… Co-author DOI 10.1016/j.esmoop.2025.105874↗
  5. The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cam4.6111↗
  6. Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine pl… Co-author DOI 10.1016/j.dld.2022.11.012↗
  7. How to improve metastatic pancreatic ductal adenocarcinoma patients' selection: Between clinical trials and the real-world. Co-author DOI 10.5306/wjco.v13.i5.417↗
  8. BRCA-mutant pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-021-01469-9↗
  9. Uncovering key targets of success for immunotherapy in pancreatic cancer. Co-author DOI 10.1080/14728222.2021.2010044↗
  10. Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus. Co-author DOI 10.1177/0300891620976945↗
  11. New therapeutic targets in pancreatic cancer. Co-author DOI 10.1016/j.ctrv.2019.101926↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mario Scartozzi · 10 shared papers, 2019–2026 · strength 1.40
  2. Letizia Procaccio · 4 shared papers, 2023–2026 · strength 0.74
  3. Eleonora Lai · 6 shared papers, 2019–2023 · strength 0.68
  4. Caterina Vivaldi · 3 shared papers, 2025–2026 · strength 0.59
  5. Monica Niger · 3 shared papers, 2025–2026 · strength 0.59
  6. Giampaolo Tortora · 3 shared papers, 2025–2026 · strength 0.59
  7. Sara Lonardi · 3 shared papers, 2023–2026 · strength 0.55
  8. Mariacristina Di Marco · 2 shared papers, 2026 · strength 0.42
  9. Federico Nichetti · 2 shared papers, 2026 · strength 0.41
  10. Lisa Salvatore · 2 shared papers, 2025–2026 · strength 0.39
  11. Michèle Milella · 2 shared papers, 2023–2026 · strength 0.36
  12. Simona Casalino · 2 shared papers, 2023–2026 · strength 0.33
  13. Elisa Giommoni · 2 shared papers, 2023–2026 · strength 0.33
  14. Ferdinando De Vita · 2 shared papers, 2023–2026 · strength 0.33
  15. Francesca Bergamo · 2 shared papers, 2023–2026 · strength 0.33
  16. Guido Giordano · 2 shared papers, 2023–2026 · strength 0.33
  17. Davide Melisi · 2 shared papers, 2023–2026 · strength 0.33
  18. Alberto Zaniboni · 2 shared papers, 2023–2026 · strength 0.33
  19. Giulia Orsi · 2 shared papers, 2021–2026 · strength 0.32
  20. Lorenzo Antonuzzo · 2 shared papers, 2023–2025 · strength 0.32
  21. Marina Macchini · 1 shared paper, 2026 · strength 0.22
  22. Giuseppe Malleo · 1 shared paper, 2026 · strength 0.22
  23. Stefano Partelli · 1 shared paper, 2026 · strength 0.22
  24. Nicolò Pecorelli · 1 shared paper, 2026 · strength 0.22
  25. Catia Carconi · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.